A randomized dose-escalation study on the safety, tolerability, immunogenicity, pharmacokinetics and pharmacodynamics of a novel recombinant human albumin in healthy subjects

医学 耐受性 药效学 药代动力学 安慰剂 药理学 免疫原性 内科学 不利影响 胃肠病学 白蛋白 免疫学 抗体 病理 替代医学
作者
Cuiyun Li,Wei Xiang,Min Wu,Hong Zhang,Jianqiu Cheng,Tao Yang,Jiajia Mai,Xiumei Chi,Xiuzhu Gao,Yanhua Ding,Junqi Niu
出处
期刊:European Journal of Pharmaceutical Sciences [Elsevier BV]
卷期号:165: 105923-105923 被引量:5
标识
DOI:10.1016/j.ejps.2021.105923
摘要

Recombinant human albumin (rHA) is an alternative to human serum albumin (HSA) for treating ascites in cirrhosis patients. This study was to evaluate the safety, tolerability, immunogenicity, and pharmacokinetics/pharmacodynamics (PK/PD) of rHA in healthy subjects to guide the design for further clinical trials. Healthy subjects aged 18–55 years were enrolled in this double-blinded, first-in-human, placebo-controlled single ascending dose (SAD) (1.25, 5, 10, 20, or 30g) and positive-controlled multiple-dose study (3-day treatment of 10g/day for three cycles every three weeks). The safety was assessed by adverse events (AEs). Antibodies (IgE and IgD) and cytokines were analyzed for immunogenicity. Serum albumin levels and changes in plasma colloid osmotic pressure (PCOP) and hematocrit (HCT) were measured for PK/PD analysis. rHA was well tolerated as all AEs were assessed as mild or moderate. No severe allergy or difference in the incidence of AEs was observed among the different cohorts in the SAD study or in the different cycles in the multiple-dose study. The incidence of AEs was similar for the rHA and HSA cohort. Antibodies or cytokines showed no changes after drug administration. As expected, serum albumin levels and PCOP increases, and HCT ratio decreases were dose-related with significant differences (p < 0.01). No differences were observed between rHA and HSA. rHA is safe and well-tolerated in healthy Chinese subjects. rHA and HSA exhibited similar safety, tolerability, and PK/PD profiles. The results support further evaluation of rHA treatment in cirrhotic patients with ascites. The clinical trial registration numbers are CTR20191221 (http://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
量子星尘发布了新的文献求助10
刚刚
刚刚
CAOHOU应助sue采纳,获得10
1秒前
1秒前
Loik完成签到,获得积分10
4秒前
4秒前
苗条梦玉发布了新的文献求助10
5秒前
5秒前
5秒前
10秒前
绛川发布了新的文献求助10
11秒前
momo发布了新的文献求助10
12秒前
搜集达人应助潘善若采纳,获得10
12秒前
yyer发布了新的文献求助10
13秒前
实心小墩墩完成签到,获得积分10
15秒前
20秒前
21秒前
香蕉觅云应助su采纳,获得10
21秒前
深情安青应助momo采纳,获得10
23秒前
23秒前
24秒前
可爱的函函应助hu采纳,获得10
26秒前
26秒前
27秒前
ABS发布了新的文献求助10
27秒前
28秒前
FashionBoy应助忘记时间采纳,获得30
29秒前
爆米花应助无情的匪采纳,获得10
30秒前
31秒前
刘寄奴发布了新的文献求助10
32秒前
su发布了新的文献求助10
34秒前
深情安青应助胡航航采纳,获得10
35秒前
小小发布了新的文献求助30
36秒前
CodeCraft应助苗条梦玉采纳,获得10
37秒前
jia完成签到 ,获得积分10
38秒前
41秒前
41秒前
42秒前
Ava应助坚定路人采纳,获得10
44秒前
46秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989297
求助须知:如何正确求助?哪些是违规求助? 3531418
关于积分的说明 11253893
捐赠科研通 3270097
什么是DOI,文献DOI怎么找? 1804884
邀请新用户注册赠送积分活动 882087
科研通“疑难数据库(出版商)”最低求助积分说明 809158